Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Canadian Journal of Gastroenterology and Hepatology

Volumn 2016, Issue , 2016, Pages

  Beilman, Candace L ^a   Thanh, Nguyen Xuan ^b   Ung, Victoria ^a   Ma, Christopher ^a   Wong, Karen ^a   Kroeker, Karen I ^a   Lee, Thomas ^a   Wang, Haili ^a   Ohinmaa, Arto ^b   Jacobs, Phil ^b   Halloran, Brendan P ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH STATUS; HUMAN; ILEITIS; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STEROID THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; ALBERTA; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HEALTH CARE DELIVERY; ONTARIO; REMISSION; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ALBERTA; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; ONTARIO; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84992381897     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2016/5315798     Document Type: Article

References (42)

1. E. F. Stange, S. P. L. Travis, S. Vermeire et al., "European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis, " Journal of Crohn's and Colitis, vol. 2, no. 1, pp. 1-23, 2008.
2. R. N. Fedorak, K. Wong, and R. Bridges, "Canadian digestive health foundation public impact series. Inflammatory bowel disease in Canada: incidence, prevalence, and direct and indirect economic impact, " Canadian Journal of Gastroenterology, vol. 24, no. 11, pp. 651-655, 2010.
3. W. Reinisch, W. J. Sandborn, D. W. Hommes et al., "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, " Gut, vol. 60, no. 6, pp. 780-787, 2011.
4. S. C. Manson, R. E. Brown, A. C. Cerulli, and C. F. Vidaurre, "The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use, " RespiratoryMedicine, vol. 103, no. 7, pp. 975-994, 2009.
5. I. E. Berndtsson, E. K. Carlsson, E. I. Persson, and E. A. Lindholm, "Long-termadjustment to living with an ileal pouch-anal anastomosis, " Diseases of the Colon and Rectum, vol. 54, no. 2, pp. 193-199, 2011.
6. E. J. Simchuk and R. C. Thirlby, "Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses, " World Journal of Surgery, vol. 24, no. 7, pp. 851-856, 2000.
7. N. Gies, K. I. Kroeker, K. Wong, and R. N. Fedorak, "Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort, " Alimentary Pharmacology andTherapeutics, vol. 32, no. 4, pp. 522-528, 2010.
8. W. Reinisch, W. J. Sandborn, R. Panaccione et al., "52-Week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants, " Inflammatory Bowel Diseases, vol. 19, no. 8, pp. 1700-1709, 2013.
9. W. J. Sandborn, G. Van Assche, W. Reinisch et al., "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, " Gastroenterology, vol. 142, no. 2, pp. 257-265. e3, 2012.
10. J.-F. Colombel, W. J. Sandborn, S. Ghosh et al., "Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative Colitis: data from ULTRA 1, 2, and 3, " American Journal of Gastroenterology, vol. 109, no. 11, pp. 1771-1780, 2014.
11. B. G. Feagan, R. Panaccione, W. J. Sandborn et al., "Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study, " Gastroenterology, vol. 135, no. 5, pp. 1493-1499, 2008.
12. Alberta Health and Wellness, "Alberta Health and Wellness Drug Benefit List [Alberta Blue Cross web site], " 2015, https://www. Ab. bluecross. ca/dbl/publications. html.
13. E. V. Loftus Jr., S. J. Johnson, A. P. Yu et al., "Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease, " European Journal of Gastroenterology & Hepatology, vol. 21, no. 11, pp. 1302-1309, 2009.
14. K. Bodger, T. Kikuchi, and D. Hughes, "Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporatingUnited Kingdompatient-level cost data, " Alimentary Pharmacology andTherapeutics, vol. 30, no. 3, pp. 265-274, 2009.
15. G. Blackhouse, N. Assasi, F. Xie et al., "Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-drugs for refractory Crohn's disease, " Journal of Crohn's and Colitis, vol. 6, no. 1, pp. 77-85, 2012.
16. J. T. Heikens, J. de Vries, and C. J. H. M. van Laarhoven, "Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouchanal anastomosis for ulcerative colitis: A systematic review, " Colorectal Disease, vol. 14, no. 5, pp. 536-544, 2012.
17. L. M. Lix, L. A. Graff, J. R. Walker et al., "Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease, " Inflammatory Bowel Diseases, vol. 14, no. 11, pp. 1575-1584, 2008.
18. A. Waljee, J. Waljee, A. M. Morris, and P. D. R. Higgins, "Threefold increased risk of infertility: A meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis, " Gut, vol. 55, no. 11, pp. 1575-1580, 2006.
19. V. Ung, N. X. Thanh, K. Wong et al., "Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis, " Clinical Gastroenterology andHepatology, vol. 12, no. 11, pp. 1871-1878, 2014.
20. Canadian Agency for Drugs and Technologies in Health, "Guidelines for the Economic Evaluation of Health Technologies: Canada [CADTH web site], " 2006, http://www. inahta. org/wp-content/themes/inahta/img/AboutHTA Guidelines for the Economic Evaluation of Health Technologies. pdf.
21. Alberta Health Care Insurance Plan [Alberta Health and Wellness web site], 2014, http://www. health. Alberta. ca/professionals /SOMB. html.
22. OCCI (Ontario Case Costing Initiative), Costing analysis tool (CAT), OCCI web site, 2015, http://www. occp. com.
23. C. Ma, V. Huang, D. Fedorak et al., "Outpatients with ulcerative colitis being treated with adalimumab and infliximab have similar rates of loss of response, " Canadian Journal of Gastroenterology and Hepatology, vol. 28, article A141, 2014.
24. A. Oussalah, C. Laclotte, J.-B. Chevaux et al., "Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: A single-centre experience, " Alimentary Pharmacology and Therapeutics, vol. 28, no. 8, pp. 966-972, 2008.
25. F. Baert, E. Glorieus, C. Reenaers et al., "Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients, " Journal of Crohn's and Colitis, vol. 7, no. 2, pp. 154-160, 2013.
26. K. O. Arseneau, S. Sultan, D. T. Provenzale et al., "Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis" Clinical Gastroenterology and Hepatology, vol. 4, no. 9, pp. 1135-1142, 2006.
27. W. Afif, J. A. Leighton, S. B. Hanauer et al., "Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab, " Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1302-1307, 2009.
28. C. Taxonera, J. Estellés, I. Fernández-Blanco et al., "Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab, " Alimentary Pharmacology andTherapeutics, vol. 33, no. 3, pp. 340-348, 2011.
29. E. McDermott, S. Murphy, D. Keegan, D. O'Donoghue, H. Mulcahy, and G. Doherty, "Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis, " Journal of Crohn's and Colitis, vol. 7, no. 2, pp. 150-153, 2013.
30. S. D. Grosse, "Assessing cost-effectiveness in healthcare: history of the $50, 000 per QALY threshold, " Expert Review of Pharmacoeconomics and Outcomes Research, vol. 8, no. 2, pp. 165-178, 2008.
31. A. M. Ternouth, M. Chapman, and R. Modha, "An assessment of the variation in accepted ICERs by disease type: results from four HTAS (poster), " in Proceedings of the Health Technology Assessment: A European Collaboration, ISPOR 13th Annual European Congress, Prague, Czech Republic, November 2010.
32. A. Rocchi, D. Menon, S. Verma, and E. Miller, "The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond, " Value in Health, vol. 11, no. 4, pp. 771-783, 2008.
33. R. Panaccione, S. Ghosh, S. Middleton et al., "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, " Gastroenterology, vol. 146, no. 2, pp. 392-400. e3, 2014.
34. F. Carbonnel, J. F. Colombel, J. Filippi et al., "Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis, " Gastroenterology, vol. 150, no. 2, pp. 380-388. e4, 2016.
35. K. G. Saag, R. Koehnke, J. R. Caldwell et al., "Low dose longterm corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events, " The American Journal of Medicine, vol. 96, no. 2, pp. 115-123, 1994.
36. P. Rutgeerts, W. J. Sandborn, B. G. Feagan et al., "Infliximab for induction and maintenance therapy for ulcerative colitis, " The New England Journal of Medicine, vol. 353, no. 23, pp. 2462-2476, 2005.
37. S. D. Holubar, K. H. Long, E. V. Loftus, B. G. Wolff, J. H. Pemberton, and R. R. Cima, "Long-termdirect costs before and after proctocolectomy for ulcerative colitis: A population-based study in olmsted county, Minnesota, " Diseases of the Colon and Rectum, vol. 52, no. 11, pp. 1815-1823, 2009.
38. K. Arai, K. Koganei, H. Kimura et al., "Incidence and outcome of complications following restorative proctocolectomy, " American Journal of Surgery, vol. 190, no. 1, pp. 39-42, 2005.
39. K. McMullen, T. C. Hicks, J. E. Ray, J. B. Gathright, and A. E. Timmcke, "Complications associated with heal pouch-anal anastomosis, " World Journal of Surgery, vol. 15, no. 6, pp. 763-766, 1991.
40. M. Barreiro-De Acosta, O. Garca-Bosch, J. Gordillo et al., "Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: A case series, " European Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 756-758, 2012.
41. P. Gionchetti, G. Straforini, R. Tambasco et al., "M1085 Use of infliximab and adalimumab in refractory pouchitis, " Gastroenterology, vol. 138, no. 5, supplement 1, p. S-328, 2010.
42. C. Ma, V. Huang, D. K. Fedorak et al., "Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease, " Alimentary Pharmacology and Therapeutics, vol. 40, no. 9, pp. 1044-1055, 2014.